Regional variations in baseline characteristics of cardiac rhythm device recipients: The PANORAMA observational cohort study

Fawziah Al Kandari a,1, Andrejs Erglis b,1, Raed Sweidan c,1, Ingrid Dannheimer d,1, Milan Sepsie e,1, Juan Bénézet f,1, Michał Padour e,1, Ajay Naik b,1, Jaime Escudero g,1, Teena West h,1, Reece Holbrook k,⁎,1, Faizel Lorgat l,1, On behalf of the PANORAMA investigators

a Cardiology Department, Kuwait Cardiac Center, Kuwait
b Cardiology Department, P. Stradins Clinical University Hospital, Riga, Latvia
c Cardiology Department, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia
d Cardiology Department, Eugene Marais Hospital, Pretoria, South Africa
e Department of Internal Medicine—Cardiology, University Hospital Brno, Brno, Czech Republic
f Cardiology Department, Hospital General de Ciudad Real, Ciudad Real, Spain
g Cardiology Department, Karlovarska Krajiska Nemocnice a.s, Karlovy Vary, Czech Republic
h Cardiology Department, Care Institute of Medical Sciences, CIMS Hospital, Gujarat, India
i Cardiology Department, Hospital Carlos Arvelo, Caracas, Venezuela
j Medtronic Bakken Research Center, Maastricht, The Netherlands
k Medtronic, Inc., Minneapolis, USA
l Cardiology Department, Christiaan Barnard Memorial Hospital, Cape Town, South Africa

ARTICLE INFO

Article history:
Received 14 May 2014
Accepted 30 June 2014
Available online 6 July 2014

Keywords:
Cardiac pacing
Defibrillators
Cardiac resynchronization
Bradycardia
Tachycardia
Heart failure

ABSTRACT

Background: The PANORAMA study was designed to collect concurrent data on subjects from different worldwide regions implanted with CRM devices.

Methods: In this prospective, multi-center study, we analyzed baseline data on 8586 subjects implanted with CRM devices with no additional selection criteria (66% pacemaker (IPG), 16% implantable cardiac defibrillators (ICD), 17% cardiac resynchronization therapy (CRT)) and <1% Internal Loop Recorder) from 156 hospitals across 6 geographical regions between 2005 and 2011.

Results: Regardless of the device implanted, subjects from the Middle East and India often had more diabetes than other regions. Eastern and Western Europe had higher rates of atrial fibrillation reported, and men were more likely to smoke than women (46% vs 11%, p = 0.001). Within the CRT cohort there was significant variation in the proportion of males receiving a device, ranging from 55% in India to 83% in Eastern Europe.

Conclusions: We provide comprehensive descriptive data on patients receiving CRM devices from a range of geographies that are not typically reported in literature. We found significant variations in clinical characteristics and implant practices. Long term follow-up data will help evaluate if these variations require adjustments to outcome expectations.

© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

Device therapies for treating cardiac rhythm disorders include pacemakers (IPG) and implantable cardiac defibrillators (ICD), both with and without cardiac resynchronization therapy (CRT). Randomized trials have established the effectiveness of device therapies for cardiac rhythm and disease management [1–5]. These trials have played an important role in establishing guidelines for the application of these therapies.

Translating evidence from randomized trials into global clinical practice guidelines involves extrapolating results from a study cohort to the population of interest in the guideline. However it is not a priori certain that study results from a specific patient population in a specific region can be extrapolated to a less well-defined patient population or to other geographies. Regional variations in disease incidence [6–8], patient demographics and comorbidities [9], genetics [10], healthcare systems and reimbursement conditions [11], cultural attitudes to

http://dx.doi.org/10.1016/j.ijchv.2014.06.008
2214-7632/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
disease and implant practices exist which affect the choice of therapy and may influence the expected therapy outcomes [12]. Risk factors can be considered and treated differently across geographies [13] and approaches to diagnostic testing can also differ. Understanding the patients, the practice patterns and the healthcare settings of a geography are important for setting expectations and interpreting patient outcomes.

While randomized trials are indispensable in understanding the benefit of therapies in strictly controlled settings, observational studies are designed to assess the relevance and credibility of clinical trial outcomes largely from registries conducted in North America and Europe. The current understanding of the real world application of cardiac rhythm management (CRM) therapies are designed to assess the relevance and credibility of clinical trial outcomes largely from registries conducted in North America and Europe [15,16]. To date there is little evidence available to shed light on regional differences in practice patterns, particularly to understand demographics, comorbidities and treatment patterns in emerging geographies.

This is the first report of the world wide PANORAMA study, a long term, multi-center, prospective, non-randomized observational study. The primary purpose of the study was to construct a computerized database of national profiles and epidemiological data on patients wearing Medtronic implantable pacemakers, cardioverter defibrillators (both with and without cardiac resynchronization therapy), and implantable loop recorders. The study was conducted in 34 countries across 6 geographical regions. Minimal selection criteria ensured that the study population included elderly patients, patients with comorbidities and patients presenting for a replacement device in an effort to ensure that participants were representative of patients receiving therapy for cardiac rhythm disorders. The objective of this analysis is to describe the patients and implant procedures and to provide information on clinical characteristics in regions previously underrepresented.

2. Methods

2.1. Study population

Consenting patients included those who were implanted (either de novo device or replacement) with a Medtronic market-released CRM device (IPG or ICD with or without CRT capability); no other selection criteria were applied. The protocol specified that enrollment should take place within 30 days of the planned/performed implant procedure.

PANORAMA (ClinicalTrials.gov Identifier: NCT00382525) was designed and conducted in compliance with the local ethical considerations and according to the principles outlined in the ‘World Medical Association Declaration of Helsinki’ (October 2000) and the laws and regulations in the countries in which the study was conducted. The study was submitted to locally appointed ethics committees and informed consent was obtained from the subjects (or their guardians).

Patients were enrolled from 6 geographies: Latin America (Argentina, Bahamas, Brazil, Colombia, Dominican Republic, Ecuador, Mexico, Puerto Rico, Uruguay, Venezuela, and Virgin Islands), Western Europe (Austria, Belgium, Denmark, Spain, Germany, Greece, Luxembourg, Netherlands, and United Kingdom), Eastern Europe (Belarus, Czech Republic, Latvia, Lithuania, Poland, Romania, Russian Federation, Serbia, Slovakia, and Turkey), Middle East (Kuwait and Saudi Arabia), South Africa and India.

2.2. Study design

Patients were assessed at study entry and during follow-up visits for at least 1 year after implant. Patients were followed according to the standard follow-up visit scheme of the participating centers, and did not require any procedures beyond regular practice. All treatment decisions were at the discretion of the treating physician. PANORAMA was designed to enroll 10,000 patients.

2.3. Data collection and measures

Clinical data were collected by the investigators using an electronic case report form designed specifically for the study, and stored in a centralized database. The data collected at baseline included demographic and clinical characteristics, medical history, and cardiovascular pharmacological therapy. At implant, data were collected on the implantation procedure and techniques, adverse experiences and device programming.

The IPG cohort includes patients implanted with a single or dual chamber pacemaker. Indications were defined as: AV block (any form of atrioventricular conduction disorder), sinus node disease (any form of atrial based bradycardia) or other (neither of the previous two). The ICD cohort includes patients implanted with a single or dual chamber ICD. Indications were defined as: secondary prevention (survivor of prior sustained ventricular tachyarrhythmia) or primary prevention (risk factors for sudden cardiac arrest without prior episode). The CRT cohort includes patients implanted with a CRT-D or a CRT-P.

2.4. Statistics

Data are reported as mean ± standard deviation (SD), median (interquartile range (IQR)) or as n (percentage). For continuous variables, comparisons across the regional groups were made using analysis of variance (ANOVA) with pairwise comparisons performed using Tukey’s studentized range test. For categorical variables a chi-square test was used. All statistical analyses were performed using SAS software version 9.3 (SAS Institute). P values less than 0.05 were considered statistically significant. Stratification of the analysis was specified a priori by region, pathology, indication, and device type.

3. Results

A total of 10,064 subjects were enrolled in the PANORAMA study between 2005 and 2011. From the total study population 1478 patients were excluded from the database due to the lack of evidence of a signed Patient Informed Consent or Patient Data Release Form (1428), or because the same patient was, by mistake, created twice in the electronic database (50). This analysis includes data of the remaining 8586 subjects, all implanted with a CRM device, and enrolled by 156 centers across 34 countries. Two thirds of the study population was implanted with an IPG, 16% with ICD, 17% with CRT, and 1% were implanted with an implantable loop recorder or missing information about the device type. One third of the subjects were enrolled from Eastern Europe (EE), 17% from Western Europe (WE), 17% from South Africa (SA), 17% from the Middle East (ME), 13% from Latin America (LA) and 7% from India (IN) (Table 1).

Regardless of the type of device implanted, several cardiovascular risk factor patterns were noted to be similar. In particular, subjects from the Middle East had substantially more diabetes present than other regions (47% vs 20% EE, 19% LA, 15% SA, 25% WE, 33% IN, p < 0.001 for ME vs all); subjects from India were significantly lighter in weight (66 ± 13 kg vs 81 ± 16 EE, 71 ± 15 LA, 82 ± 20 SA, 79 ± 16 WE, 76 ± 19 ME, p < 0.001 for IN vs all) and in all regions men were more likely to smoke than females (46% vs 11%, p < 0.001).

There were also distinct differences in the amount of atrial fibrillation reported across the regions with Eastern and Western Europe reporting more atrial fibrillation than other regions (42% EE and 36% WE vs 15% LA, 15% ME, 26% SA, 9% IN, p < 0.001 for EE vs all and p < 0.05 for WE vs all).

The use of general anesthesia for all types of device implants was higher in Latin America than in other regions (26% vs 2% EE, 1% IN, 2% ME, 12% SA, 14% WE, p < 0.001 for LA vs all).

In the IPG cohort 46% were female and 41% were aged over or equal to 75 years of age. Table 2 reports the baseline and initial treatment characteristics of patients who received IPG therapy stratified by region.
There were significant differences in median age across the regions ranging from 65 years in the Middle East and India to 76 years in Western Europe \((p < 0.001)\), which remained even after adjusting for replacement device. AV block as a primary indication for implant was more common in India (77%) and the Middle East (66%) and least frequent in South Africa (26%) \((p < 0.001)\). 22% of the IPG cohort was implanted with a single chamber device, persistent or permanent AF had not been reported. In 62% of the patients implanted with a single chamber device, persistent or permanent AF had not been reported.

**Table 2**

Baseline demographics, device and implant characteristics for the IPG cohort by region.

| Characteristics               | Total n = 5592 | Eastern Europe n = 1769 | India n = 368 | Latin America n = 840 | Middle East n = 782 | South Africa n = 827 | Western Europe n = 1006 |
|-------------------------------|----------------|------------------------|--------------|-----------------------|---------------------|----------------------|--------------------------|
| Median age, years (IQR)       | 72 (63,79)     | 73 (66,79)             | 65 (56,74)   | 74 (64,80)            | 65 (51,74)          | 72 (62,80)           | 76 (70,81)               |
| Male                          | 3030 (54)      | 884 (50)               | 236 (64)     | 431 (51)              | 406 (52)            | 461 (56)             | 612 (61)                 |
| Indication                    |                |                        |              |                       |                     |                      |                          |
| Sinus node dysfunction        | 2421 (43)      | 920 (52)               | 75 (20)      | 266 (32)              | 187 (24)            | 512 (62)             | 461 (46)                 |
| AV block                      | 2733 (49)      | 686 (39)               | 283 (77)     | 529 (62)              | 561 (72)            | 218 (26)             | 465 (46)                 |
| Othera                        | 431 (8)        | 161 (9)                | 10 (3)       | 54 (6)                | 34 (4)              | 95 (11)              | 77 (8)                   |
| Body mass index (kg/m²)       | 27 (5.3)       | 28 (4.7)               | 25 (4.4)     | 26 (4.4)              | 29 (6.9)            | 27 (5.8)             | 27 (4.5)                 |
| Male/weight/obeseb            | 2914 (52%)     | 1033 (58%)             | 170 (46%)    | 416 (50%)             | 522 (67%)           | 363 (44%)            | 410 (41%)                |
| Previous or current smoker    | 1558 (28)      | 478 (27)               | 55 (15)      | 299 (36)              | 172 (22)            | 160 (19)             | 394 (39)                 |
| Hypertension                  | 3418 (61)      | 1321 (75)              | 164 (45)     | 531 (63)              | 425 (54)            | 376 (46)             | 601 (60)                 |
| Diabetes                      | 1258 (23)      | 379 (21)               | 118 (32)     | 166 (20)              | 292 (37)            | 109 (13)             | 194 (19)                 |
| Coronary artery disease       | 1256 (23)      | 441 (25)               | 133 (36)     | 103 (12)              | 156 (20)            | 206 (25)             | 217 (22)                 |
| Prior myocardial infarction   | 477 (9)        | 237 (13)               | 17 (5)       | 42 (5)                | 44 (6)              | 54 (7)               | 83 (8)                   |
| Coronary artery bypass grafting | 340 (6)       | 93 (5)                 | 30 (8)       | 25 (3)                | 48 (6)              | 91 (11)              | 53 (5)                   |
| Mean ejection fraction, % (SD)| 57 (11.9)      | 55 (10.4)              | 54 (11.4)    | 59 (11.8)             | 54 (11.6)           | 59 (12.6)            | 60 (12.8)                |

| NYHA                           |                |                        |              |                       |                     |                      |                          |
| I                             | 742 (13)       | 369 (21)               | 26 (7)       | 122 (15)              | 50 (6)              | 35 (4)               | 140 (14)                 |
| II                            | 1273 (23)      | 768 (43)               | 109 (30)     | 147 (18)              | 45 (6)              | 54 (7)               | 150 (15)                 |
| III                           | 340 (6)        | 168 (10)               | 52 (14)      | 43 (5)                | 9 (1)               | 19 (2)               | 49 (5)                   |
| IV                            | 44 (1)         | 11 (1)                 | 3 (1)        | 4 (1)                 | 3 (1)               | 18 (2)               | 5 (1)                    |
| No heart failure              | 3175 (57)      | 451 (26)               | 178 (48)     | 523 (62)              | 674 (86)            | 700 (85)             | 650 (65)                 |

| Atrial fibrillation           |                |                        |              |                       |                     |                      |                          |
| Paroxysmal                    | 1093 (20)      | 586 (33)               | 33 (9)       | 69 (8)                | 57 (7)              | 83 (10)              | 265 (26)                 |
| Persistent/permanent          | 847 (11)       | 226 (13)               | 5 (1)        | 75 (9)                | 73 (9)              | 133 (16)             | 115 (11)                 |
| CHADS2 score 2 or more        | 2960 (53)      | 1192 (67)              | 170 (46)     | 438 (52)              | 326 (42)            | 287 (35)             | 547 (54)                 |
| Single chamber device         | 1236 (22)      | 363 (21)               | 57 (16)      | 210 (25)              | 233 (30)            | 252 (31)             | 121 (12)                 |

| Specialization of implanting physicianc |                |
| Electrophysiologist           | 2122 (38)      | 436 (25)               | 363 (99)     | 385 (46)              | 741 (95)            | 124 (15)             | 73 (7)                   |
| Cardiologist                  | 2516 (45)      | 765 (43)               | 3 (1)        | 237 (28)              | 9 (1)               | 702 (85)             | 800 (80)                 |
| Surgeon                       | 919 (16)       | 565 (32)               | 2 (1)        | 211 (25)              | 15 (2)              | 0 (0)                | 126 (13)                 |
| EP or cardiac catheter lab implant setting | 4212 (75) | 1199 (68)              | 364 (99)     | 617 (74)              | 763 (98)            | 812 (98)             | 457 (45)                 |
| General anesthesia            | 372 (7)        | 7 (1)                  | 4 (1)        | 178 (21)              | 24 (3)              | 59 (7)               | 100 (10)                 |

| IPG = implantable pulse generator; EP = electrophysiology; IQR = interquartile range; SD = standard deviation. |
| Other includes syncope, (bradycardia due to) atrial fibrillation and supraventricular arrhythmia. |
| Obesity defined as BMI (kg/m²) between 25 and 29 and obese defined as BMI > 30. |
| Specialization of physician was self-reported. |
threshold testing (DFT) at implant varied between regions from 35% in the Middle East to 85% in South Africa. There was no difference in age or gender when comparing patients who received defibrillation testing to those who did not receive defibrillation testing. A decline in the proportion of patients receiving defibrillation testing over time (2005–2011 48%, p for trend = 0.001) was seen.

The CRT cohort was of similar age with the ICD cohort and younger than the IPG cohort (63 years vs 61 (ICD) and 72 (IPG)). Table 4 reports the baseline and initial treatment characteristics of patients who received CRT therapy stratified by region. Notable differences between regions in subject demographics include male gender ranging from 55% in India to 83% in Eastern Europe, and median age ranging from 58 years in India to 73 years in Western Europe. Regional variation in the use of CRT-D vs CRT-P was considerable with 85% of the CRT devices implanted in the Middle East having defibrillator functionality compared to only 12% in South Africa. 20% of the CRT-D cohort was female compared to 33% of the CRT-P cohort, p = 0.001. In those that had QRS data available, less than half of the CRT recipients in South Africa, had a QRS > 120 ms. 50% of the patients had the LV lead implanted in the posterolateral location, but in a significant percentage of patients in Eastern Europe and Latin America, the LV lead was implanted in the middle lateral vein location. The use of defibrillation threshold testing (DFT) for CRT-D device implants varied between regions from 7% in South Africa to 30% in Latin America.

### 4. Discussion

The PANORAMA database provides unprecedented observational data collected from more than 8500 subjects being treated for cardiac rhythm disturbances from diverse geographies, facilitating comparisons and examination of patient demographics, disease comorbidities, and implant practices. Despite some difficulties associated with conducting research outside of the usual western settings, the importance of including such subjects should not be underestimated; majority of RCT data affects genetic and environmental differences and likely reflects genetic and environmental differences and dietary preferences [9,18,19]. Differences across the regions were most pronounced when looking at the indications and type of device, for example in India, Latin America and the Middle East, there was more use of IPG therapy in AV block (a more stark presentation) than sinus node disease and in South Africa very few ICDs were implanted for primary prevention. It is likely that these differences reflect the economic situation and reimbursement and insurance structures within a country.
however, there also seems to be an evolution in pacing indication, from primarily AV block in the early regional pacing era to more sinus node disease when cardiac pacing has become more common [20]. Of the 34 participating countries, 71% are considered to be emerging or developing economies, based on International Monetary Fund (IMF) guidelines [21]. This represents 82% of the study population.

The diagnosis of AF appeared to be comparatively low in Latin America, India and the Middle East. Recent evidence is indicating that even small amounts of AF regardless of symptoms may be correlated with increased stroke risk [22].

Also seen were expected patterns such as the higher use of general anesthesia which reflects local preferences. Other observations were more difficult to explain such as DFT at implants for ICD devices with and without CRT capability. This may reflect changing attitudes about the clinical need for DFT at implant, for which the evidence base is growing [23–25].

In general, the PANORAMA IPG cohort overall was similar to previously reported cohorts. Compared to the DINAMIT and MADIT-II trials, the PANORAMA ICD cohort had slightly more comorbidities present at implant [26,27] but when compared with previous secondary prevention studies our cohort was similar [28]. We saw a higher prevalence of single chamber ICD use, predominantly in Western Europe, India and South Africa as compared to other regions. This may not only be reflective of economic realities, but may also indicate differing attitudes regarding the level of evidence available for patients without a pacemaker indication [29]. The PANORAMA study included CRT patients with a fairly typical patient profile. When compared to the European CRT survey [16] our cohort was of similar age but had more CRT-P patients and slightly more patients with NYHA II. There were a number of patients receiving CRT therapy despite the lack of documentation of a QRS duration greater than 120 ms. Although it might be possible that the QRS duration has been less documented for those patients with a QRS duration greater than 120 ms, it might also be that the PANORAMA reflects real clinical practice of implanting CRT devices for other (clinical) reasons, irrespective of the QRS duration. There is evidence that CRT devices are electively implanted in patients with a QRS

---

**Table 4**

Baseline demographics, device and implant characteristics for CRT cohort by region.

| Characteristic | Total | Eastern Europe | India | Latin America | Middle East | South Africa | Western Europe |
|---------------|-------|----------------|-------|---------------|-------------|--------------|----------------|
| **n = 1455 n (%)** |       | n = 400 n (%)  | n = 108 n (%) | n = 116 n (%) | n = 276 n (%) | n = 469 n (%) | n = 86 n (%)    |
| Median age, years (IQR) | 63 (54,71) | 59 (51,87) | 58 (50,66) | 63 (53,71) | 64 (56,72) | 64 (56,72) | 73 (67,77)     |
| Male | 1052 (72) | 332 (83) | 59 (55) | 85 (73) | 199 (72) | 317 (68) | 60 (70)         |
| Body mass index (kg/m²) | 29 (6.0) | 29 (5.1) | 25 (4.1) | 26 (5.0) | 30 (6.6) | 30 (6.6) | 27 (4.7)        |
| Overweight/obesea | 886 (61%) | 260 (65%) | 44 (41%) | 52 (45%) | 206 (75%) | 277 (59%) | 47 (55%)        |
| Prior myocardial infarction | 316 (22) | 159 (40) | 10 (9) | 23 (20) | 58 (21) | 35 (8) | 31 (36)         |
| Diabetes | 433 (30) | 70 (18) | 43 (40) | 24 (21) | 172 (62) | 97 (21) | 27 (31)         |
| CHADS2 score 2 or more | 931 (64) | 265 (66) | 53 (49) | 65 (56) | 211 (76) | 285 (61) | 52 (61)         |
| NYHA I | 89 (6) | 2 (1) | 5 (4) | 5 (4) | 39 (14) | 35 (8) | 3 (4)           |
| NYHA II | 246 (17) | 42 (11) | 9 (8) | 23 (20) | 69 (25) | 90 (19) | 13 (15)         |
| NYHA III | 689 (47) | 273 (68) | 71 (66) | 55 (47) | 141 (51) | 107 (23) | 42 (40)         |
| NYHA IV | 318 (22) | 82 (21) | 23 (21) | 25 (22) | 22 (8) | 16 (4) | 3 (4)           |
| No heart failure | 93 (6) | 1 (–1) | 0 (0) | 8 (7) | 5 (2) | 74 (16) | 5 (6)           |
| QRS duration, ms | Not reported | 271 (19) | 56 (14) | 62 (57) | 37 (32) | 18 (7) | 59 (13)         |
| < 120 | 385 (27) | 42 (11) | 4 (4) | 12 (10) | 45 (16) | 275 (59) | 7 (8)           |
| 120 to 150 | 378 (26) | 120 (30) | 9 (8) | 26 (22) | 128 (46) | 79 (17) | 16 (19)         |
| > 150 | 421 (29) | 182 (46) | 33 (31) | 41 (35) | 85 (31) | 56 (12) | 24 (28)         |
| Left bundle branch block | 712 (49) | 264 (66) | 82 (76) | 49 (42) | 173 (63) | 98 (21) | 46 (54)         |
| Right bundle branch block | 81 (6) | 18 (5) | 9 (8) | 8 (7) | 29 (11) | 15 (3) | 2 (2)           |
| Atrial fibrillation | Paroxysmal | 147 (10) | 45 (11) | 3 (3) | 2 (2) | 27 (10) | 59 (13)         |
| Persistent/permanent | 223 (15) | 94 (24) | 3 (2) | 12 (10) | 22 (8) | 79 (17) | 13 (15)         |
| CHADS2 score 2 or more | 931 (64) | 265 (66) | 53 (49) | 65 (56) | 211 (76) | 285 (61) | 52 (61)         |
| CRT defibrillator | 682 (50) | 212 (53) | 31 (29) | 87 (75) | 234 (65) | 58 (12) | 60 (70)         |
| Specialization of implanting physicianb | Electrophysiologist | 775 (53) | 175 (44) | 108 (100) | 74 (64) | 273 (99) | 116 (25) |
| Cardiologist | 439 (30) | 10 (3) | 0 (0) | 22 (19) | 0 (0) | 352 (75) | 55 (64)         |
| Surgeon | 238 (16) | 215 (54) | 0 (0) | 20 (17) | 0 (0) | 1 (–1) | 2 (2)           |
| EP or cardiac catheter lab implant setting | 1246 (86) | 229 (57) | 105 (100) | 105 (91) | 275 (100) | 461 (98) | 68 (79)         |
| General anesthesia | 154 (11) | 15 (4) | 0 (0) | 45 (39) | 5 (2) | 78 (17) | 11 (13)         |
| LV lead location | Postero lateral | 545 (50) | 107 (36) | 42 (46) | 28 (33) | 86 (48) | 269 (69) |
| Middle lateral vein | 218 (20) | 90 (30) | 7 (8) | 25 (30) | 19 (11) | 69 (18) | 8 (15) |
| Basal posterior vein | 66 (6) | 15 (5) | 1 (1) | 2 (2) | 36 (20) | 8 (2) | 4 (7)           |
| Middle anterior vein | 66 (6) | 29 (10) | 5 (6) | 9 (11) | 2 (1) | 19 (5) | 2 (4)           |
| Middle posterior vein | 38 (4) | 14 (5) | 0 (0) | 7 (8) | 14 (8) | 1 (–1) | 2 (4)           |
| Other | 113 (11) | 34 (11) | 30 (33) | 8 (10) | 21 (12) | 20 (6) | 0 (0)           |
| Defibrillation testing performedc | 215 (15) | 93 (23) | 10 (9) | 35 (30) | 36 (13) | 31 (7) | 10 (12)         |

CRT = cardiac resynchronization therapy; EP = electrophysiology; LV = left ventricular; IQR = interquartile range; SD = standard deviation.

a Overweight defined as BMI (kg/m²) between 25 and 29 and obese defined as BMI > 30.

b Specialization of physician was self-reported.

c Counts and percentages based on CRT-defibrillator devices only. Percentages do not always add to 100, due to missing values.
duration below 150 ms after total AV node ablation for AF [30,31]. However, this cannot be confirmed by the PANORAMA data since prior AV nodal ablation information had not been collected.

Regardless of the reasons for heterogeneity in subjects and therapy practice these differences are likely to impact the outcomes for patients. A smoking history was present in more than 50% of the male ICD and CRT patients, and from the male patients receiving a first CRT up to 24% (Middle East) was smoking at the time of device implant. From the male patients receiving a first CRT the percentage of current smokers was up to 18% (South Africa and Eastern Europe). As failure to stop smoking will likely have a negative impact on survival of these patients, especially those with ischemic heart disease, the PANORAMA data may indicate a need to strongly emphasize smoking cessation possibilities to patients before receiving a medical device.

5. Study limitations

These data need to be interpreted in the context of the limitations of the study. This was a single-manufacturer sponsored study where specific device characteristics might limit applicability across all device manufacturers; however, an attempt was made to compare general therapy parameters that would apply regardless of the manufacturer. In this global analysis, some regions of the world were not represented, but this is the most regionally diverse dataset reported to date. The number of centers and countries represented in the data may not be sufficient to accurately characterize the full regional practice and some of the differences observed could be center specific. Some countries limited the type of device enrolled, so broad conclusions about the proportion of ICD/ICD/CRT use are not possible. To limit overinterpretation, in cases where the number of patients was limited (specific device types), general observations were avoided in this report.

Missing data could have introduced biases and where substantial data was missing it has been reported and interpreted with caution. Some of the measures of patient conditions were collected without data was missing it has been reported and interpreted with caution. The reader can interpret the clinical and statistical significance of the results.

6. Conclusions

We provide comprehensive descriptive data on patients receiving cardiac rhythm management devices from a range of geographies that is not typically reported in literature; this may aid in the interpretation and application of findings from other studies. We found significant variations in age, cardiovascular diseases, rhythm disturbances, type of device implant, and implant practices across the regions. Some of these may be reflections of larger socioeconomic variations, while others may be due to regional guidelines and practice preferences.

Sources of funding

This work was supported by the Bakken Research Center, Maastricht, Netherlands, a wholly owned division of Medtronic, Inc.

Conflicts of Interest

Fawzia Al-Kandari has received consultant honoraries from Medtronic. Juan Bénézet has received consultant honoraries and speaker fees from Medtronic. Ayaj Naik has received consultant honoraries from Medtronic, St. Jude Medical, Boston Scientific, Biotronik, Sanofi and Astra Zeneca. Teena West and Reece Holbrook are Medtronic employees.

Acknowledgments

We would like to thank all PANORAMA investigators and the PANORAMA team for their continued efforts during this long term study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.jchv.2014.06.008.

References

[1] Bardy GH, Lee KL, Mark DB, Poole JE, Packer DJ, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352(3):225–37.
[2] Young JR, Abraham WT, Smith AL, Leon AR, Liereman R, Wilkoff B, et al. Combined cardiac resynchronization and implantable cardioverter defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 2003;289(20):2685–94.
[3] Linde C, Abraham WT, Gold MR, Sutton St John M, Globo S, Daubert C, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52(23):1834–43.
[4] Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure deaths. N Engl J Med 2009;361(14):1329–38.
[5] Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363(25):2385–95.
[6] Anjama RM, Pradap Reepha Deepa M, Datta M, Sudha V, Unnikrishnan R, et al. Prevalence of diabetes and pre-diabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-India DIABetes (ICMR-INDiAB) study. Diabetologia 2011;54(12):3022–7.
[7] Yusuf S, Reddy S, Ongu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104(23):2855–64.
[8] Yusuf S, Reddy S, Ongu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104(22):2746–53.
[9] Saad H, Carruthers SG, Nagelkerke N, Al-Maskari F, Afandi B, Reed R, et al. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract 2007;78(S1):39–77.
[10] Prins BP, Lagou V, Asselbergs FW, Snider H, Pj, J. Genetics of coronary artery disease: genome-wide association studies and beyond. Atherosclerosis 2012;225(1):1–10.
[11] Bhohaji O, Beeranahalli TS, Devadasan R, Munegowda CM, Devadasan N, Criel B, et al. No longer diseases of the wealthy: prevalence and health-seeking for self-reported chronic conditions among urban poor in southern India. BMC Health Serv Res 2013;13:306.
[12] Laslett LJ, Alagona P, Clark BA, Drozdza JP, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 2012;60(Suppl.S):S5–49.
[13] Shehah A, Al-Dabbagh B, Almahmeed W, Bastani A, Agrawal A, Yusufali A, et al. Characteristics, management, and in-hospital outcomes of diabetic patients with acute coronary syndrome in the United Arab Emirates. Sci World J 2012;2012:608597.
[14] Nallamoorthy BK, Hayward RB, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118(12):1294–303.
[15] Hammill SC, Kremers MS, Stevenson LW, Heidenreich PA, Lang CM, Curtis JP, et al. Review of the registry’s fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm 2010;7(9):1340–5.
[16] Bogale N, Priori S, Cleland JG, Brugada J, Auricchio A, et al. The European CRT survey: 1 year (9–27.8). Circulation 2012;126(9):64.
[17] Mousa HG, Proclere A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009—a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol 2011;34(8):B103–27.
[18] Malik M, Balir A, Saab BA, Roklic G, King H. Glucose intolerance and associated factors in the multi-ethnic population of the United Arab Emirates: results of a national survey. Diabetes Res Clin Pract 2005;69(2):388–95.
[19] Pradap Reepha P, Prabhakaran D, Mohan V. Emerging economies and diabetes and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S59–67.
[20] Ector H, Rickards AF, Kappenberger L, Linde C, Vardas P, Oto A, et al. The world survey of cardiac pacing and implantable cardioverter defibrillators: calendar year 1997—Europe. Pacing Clin Electrophysiol 2001;24(5):863–8.
[21] World Economic Outlook Outlook and the Business Cycle April 2008. http://www.imf.org/external/pubs/ft/weo/2008/01/ International Monetary Fund; 2008 [cited 2013 8th February]. Statistical Appendix, Table F).
[22] Lip CP, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012;142(6):1489–98.
[23] Russo AM, Sauer W, Gerstenfeld EP, Hsia HH, Lin D, Cooper JM, et al. Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion? Heart Rhythm 2005;2(5):456–61.

[24] Gula LJ, Massel D, Kranz AD, Yee R, Skanes AC, Klein GJ. Is defibrillation testing still necessary? A decision analysis and Markov model. J Cardiovasc Electrophysiol 2008;19(4):400–5.

[25] Kolb C, Tzeis S, Zrenner B. Defibrillation threshold testing: tradition or necessity? Pacing Clin Electrophysiol 2009;32(5):570–2 [discussion 2].

[26] Steinberg JS, Fischer A, Wang P, Schuger C, Daubert J, McNitt S, et al. The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. J Cardiovasc Electrophysiol 2005;16(4):359–65.

[27] Dorian P, Hohnloser SH, Thorpe KE, Roberts RS, Kuck KH, Gent M, et al. Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the defibrillation in acute myocardial infarction trial (DINAMIT). Circulation 2010;122(25):2645–52.

[28] Brodsky MA, McAnulty J, Zipes DP, Baessler C, Hallstrom AP, Investigators A. A history of heart failure predicts arrhythmia treatment efficacy: data from the antiarrhythmics versus implantable defibrillators (AVID) study. Am Heart J 2006;152(4):724–30.

[29] Almendral J, Arribas F, Wolpert C, Ricci R, Adragao P, Cobos E, et al. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (dual chamber and atrial tachycardia adverse events study) trial. Europace 2008;10(5):528–35.

[30] Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J 2011;32(19):2420–9.

[31] Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace 2012;14(10):1490–7.